PhenoPath, PLLC

Diagnoses you can count on®

PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.

PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.

Latest News

  • PhenoPath acquired by Quest Diagnostics

    Please read the attached letter for an important announcement regarding PhenoPath

    Important Announcement Regarding PhenoPath

    Read More »
  • Phenomena v21.1

    New FDA Approvals for PD-L1/PD-1 Targeted Therapies & Introducing the Combined Positive Score (CPS); New Assays MUC4 IHC and TFE3 (Xp11) FISH; Amyloid Analysis;...

    Read More »
  • Phenomena v20.2 (Fall 2017)

    PhenoPath newsletter featuring the latest on RAS gene testing, "double-hit" B cell lymphomas, and a new marker for small cell carcinoma of the ovary.... Read More »